Winfried Wunderlich is a seasoned professional in the fields of nephrology, metabolic diseases, and assay development, currently serving as Vice President at Evotec since October 2016. In this role, Winfried leads preclinical portfolio strategy development and implementation, collaborating closely with internal and external partners while mentoring team members in drug discovery and biomarker identification. Prior experience includes leadership positions focused on assay development and validation at Oncotyrol and the Austrian Drug Screening Institute, where innovative drug screening methodologies were developed. Winfried's academic background includes a PhD in Cell Biology from the IMP - Research Institute of Molecular Pathology and a degree in Biochemistry from the University of Vienna, complemented by extensive research experience in drug characterization and preclinical studies.
This person is not in any teams
This person is not in any offices